Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals

JACC: Cardiovascular Interventions

Volumn 2, Issue 10, 2009, Pages 917-924

  Herrmann, Howard C ^a   Lu, Jiandong ^b   Brodie, Bruce R ^c   Armstrong, Paul W ^d   Montalescot, Gilles ^e   Betriu, Amadeo ^f   Neuman, Franz Joseph ^g   Effron, Mark B ^h   Barnathan, Elliot S ^b   Topol, Eric J ⁱ   Ellis, Stephen G ^j  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b CENTOCOR INC   (United States)

^c LeBauer Cardiovascular Research Foundation   (United States)

^d UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^h ELI LILLY AND COMPANY   (United States)

ⁱ SCRIPPS RESEARCH INSTITUTE   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

percutaneous coronary intervention; STEMI facilitation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RETEPLASE;

AGED; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; ST SEGMENT ELEVATION; SURVIVAL TIME; TREND STUDY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FIBRINOLYTIC AGENTS; HEALTH SERVICES ACCESSIBILITY; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KAPLAN-MEIERS ESTIMATE; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; PATIENT TRANSFER; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 70350023589     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.06.018     Document Type: Article

References (19)

1. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
2. DeLuca G., Suryapranata H., Ottervanga J.P., and Antman E.M. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction. Circulation 109 (2004) 1223-1225
3. Nallamothu B.K., Bates E.R., Herrin J., Wang Y., Bradley E.H., Krumholz H.M., and NRMI Investigators. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 111 (2005) 761-767
4. Herrmann H.C. Transfer for primary angioplasty: the importance of time. Circulation 111 (2005) 718-720
5. Ellis S.G., Tendera M., de Belder M.A., et al., FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358 (2008) 2277-2279
6. Morrow D.A., Antman E.M., Parsons L., et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 286 (2001) 1356-1359
7. Kozieradzka A., Kamiński K., Dobrzycki S., Nowak K., and Musiał W. TIMI risk score accurately predicts risk of death in 30-day and one-year follow-up in STEMI patients treated with primary percutaneous coronary interventions. Kardiol Pol 65 (2007) 788-795
8. Herrmann H.C., Moliterno D.J., Ohman E.M., et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) trial. J Am Coll Cardiol 36 (2000) 1489-1496
9. Herrmann H.C. Update and rationale for ongoing acute myocardial infarction trials: combination therapy, facilitation, and myocardial preservation. Am Heart J 151 Suppl (2006) S30-S39
10. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 (2006) 569-578
11. Di Mario C., Dudek D., Piscione F., et al., CARESS-in-AMI (Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction) Investigators. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 371 (2008) 559-568
12. Cantor WJ. Trial of Routine Angioplasty and Stenting After Fibrinolysis in Acute Myocardial Infarction (TRANSFER AMI). Presented at: Late Breaking Clinical Trial at American College of Cardiology; March 29-April 1, 2008; Chicago, IL.
13. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
14. Dudek D., Siudak Z., Janzon M., et al. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab-EUROTRANSFER Registry. Am Heart J 156 (2008) 1147-1154
15. Van't Hof A.W.J., Ernst N., de Boer M.J., et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. Eur Heart J 25 (2004) 837-846
16. McKay R.G., Dada M.R., Mather J.F., et al. Comparison of outcomes and safety of "facilitated" versus primary PCI in patients with ST-segment elevation myocardial infarction. Am J Cardiol 103 (2009) 316-321
17. Boersma E., and Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter?. A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 27 (2006) 779-788
18. Pinto D.S., Kirtane A.J., Nallamothu B.K., et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 114 (2006) 2019-2025
19. Gersh B.J., Stone G.W., White H.D., and Holmes Jr. D.R. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. JAMA 293 (2005) 979-986